Business
Interim Results
N4 Pharma PLC reported an operating loss of £470,216 for the six months ended June 30, 2025, a reduction from £491,705 in the prior year. The company's cash position remained strong at £1,727,543, compared to £1,204,946 in the previous year, boosted by a successful placing in April 2025 that raised £1,750,000 in gross proceeds. Basic and diluted loss per share was (0.09p) compared to (0.16p) the previous year. The company issued 87,500,000 warrants at an exercise price of 0.4p per warrant as part of the placing in April 2025. Total equity increased to £1,767,289 from £651,402 at the end of 2024. Disclaimer*
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n\n \n25 September 2025\nN4 Pharma plc\n(\"N4 Pharma\" or the \"Company\")\nInterim Results\nN4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary drug delivery system to enable advanced nucleic acid therapies for cancer and other diseases, today announces its unaudited interim results for the six months ended 30 June 2025.\n \nHighlights:\n \n· Reduced operating loss for the period to £470,216 (30 June 2024: £491,705) and R&D and general expenditure in line with budget.\n \n· Cash position remains strong, which at 30 June 2025 was £1,727,543 (30 June 2024: £1,204,946), following a successful placing in April 2025 to raise gross proceeds of £1,750,000.\n \n· Positive results from first in vivo efficacy study for N4 101 using an industry standard animal model of IBD showing a marked decrease in inflammation with both single and dual-loaded Nuvec® particles compared with controls across all key indicators of ulcerative colitis, including Disease Activity Index (DAI), colon length and body weight loss and a clear increase in efficacy using Nuvec® particles targeted to macrophages using mannose.\n \n· Appointment of Dr Alastair Smith as an independent Non-Executive Director in January 2025 and Edward Wardle as Non-Executive Director post period end.\n \n· World-class Senior Leadership Team established with leading expert consultants in drug development and research, commercial strategy and pharmaceutical manufacturing in May 2025.\n \n· Analysis of data from collaboration with world-renowned nonprofit R&D institute SRI International (\"SRI\") demonstrates the ability to specifically target cancer cells for the delivery of RNA using Nuvec®, which opens a massive market for targeted treatments in oncology.\n \n· Post-period collaboration with CMAC, based at the University of Strathclyde in Glasgow, to focus on advancing the Nuvec® platform towards clinical readiness and characterising additional dual-loaded Nuvec® preclinical candidates, both in vitro and in vivo.\n \nNigel Theobald, Chief Executive Officer of N4 Pharma plc, commented:\n \n\"The first half of the year has delivered strong pro...